Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders

Detalhes bibliográficos
Autor(a) principal: Carreira, Laura D.
Data de Publicação: 2022
Outros Autores: Matias, Francisca C., Campos, Maria G.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/103190
https://doi.org/10.3390/biomedicines10040796
Resumo: Translational research made with Cannabis sativa L. and its biocompounds provides data for some targeted diseases, as also symptoms associated with Autism Spectrum Disorders (ASDs). The main compounds ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD), are capable of modulating the endocannabinoid system since its dysregulation interferes with the pathophysiology of ASDs there are clinical evidence for its potential use in the treatment of the disease. Conventional therapy still has limitations, as it does not always treat the central symptoms, and there are many patients who do not respond to treatment, which demands more research on new therapies. Through the analysis of published literature on this topic, it is verified that cannabinoids, in particular CBD, improves symptoms associated with common comorbidities in ASDs. Some studies also demonstrate the therapeutic potential of these compounds in the treatment of central symptoms of autism. In addition, cannabinoid therapy to ASDs is associated with low adverse effects and a reduction in concomitant medication. Although it appears to be promising, it is essential to do the translation of this data into clinical research and some of its potential and critical gaps are discussed in this review pointing to large-scale and long-term clinical trials that should include more patients and homogeneous samples.
id RCAP_0cb4f5265311f842b03fcc880cf2b6cc
oai_identifier_str oai:estudogeral.uc.pt:10316/103190
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorderscannabinoidscannabidiolclinical trialanxietyFAAHsocial interactioninflammationgamma-aminobutyric acidglutamateneuroimagingTranslational research made with Cannabis sativa L. and its biocompounds provides data for some targeted diseases, as also symptoms associated with Autism Spectrum Disorders (ASDs). The main compounds ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD), are capable of modulating the endocannabinoid system since its dysregulation interferes with the pathophysiology of ASDs there are clinical evidence for its potential use in the treatment of the disease. Conventional therapy still has limitations, as it does not always treat the central symptoms, and there are many patients who do not respond to treatment, which demands more research on new therapies. Through the analysis of published literature on this topic, it is verified that cannabinoids, in particular CBD, improves symptoms associated with common comorbidities in ASDs. Some studies also demonstrate the therapeutic potential of these compounds in the treatment of central symptoms of autism. In addition, cannabinoid therapy to ASDs is associated with low adverse effects and a reduction in concomitant medication. Although it appears to be promising, it is essential to do the translation of this data into clinical research and some of its potential and critical gaps are discussed in this review pointing to large-scale and long-term clinical trials that should include more patients and homogeneous samples.2022-03-29info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/103190http://hdl.handle.net/10316/103190https://doi.org/10.3390/biomedicines10040796eng2227-9059Carreira, Laura D.Matias, Francisca C.Campos, Maria G.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-10-20T20:31:57Zoai:estudogeral.uc.pt:10316/103190Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:20:04.005509Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders
title Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders
spellingShingle Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders
Carreira, Laura D.
cannabinoids
cannabidiol
clinical trial
anxiety
FAAH
social interaction
inflammation
gamma-aminobutyric acid
glutamate
neuroimaging
title_short Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders
title_full Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders
title_fullStr Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders
title_full_unstemmed Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders
title_sort Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders
author Carreira, Laura D.
author_facet Carreira, Laura D.
Matias, Francisca C.
Campos, Maria G.
author_role author
author2 Matias, Francisca C.
Campos, Maria G.
author2_role author
author
dc.contributor.author.fl_str_mv Carreira, Laura D.
Matias, Francisca C.
Campos, Maria G.
dc.subject.por.fl_str_mv cannabinoids
cannabidiol
clinical trial
anxiety
FAAH
social interaction
inflammation
gamma-aminobutyric acid
glutamate
neuroimaging
topic cannabinoids
cannabidiol
clinical trial
anxiety
FAAH
social interaction
inflammation
gamma-aminobutyric acid
glutamate
neuroimaging
description Translational research made with Cannabis sativa L. and its biocompounds provides data for some targeted diseases, as also symptoms associated with Autism Spectrum Disorders (ASDs). The main compounds ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD), are capable of modulating the endocannabinoid system since its dysregulation interferes with the pathophysiology of ASDs there are clinical evidence for its potential use in the treatment of the disease. Conventional therapy still has limitations, as it does not always treat the central symptoms, and there are many patients who do not respond to treatment, which demands more research on new therapies. Through the analysis of published literature on this topic, it is verified that cannabinoids, in particular CBD, improves symptoms associated with common comorbidities in ASDs. Some studies also demonstrate the therapeutic potential of these compounds in the treatment of central symptoms of autism. In addition, cannabinoid therapy to ASDs is associated with low adverse effects and a reduction in concomitant medication. Although it appears to be promising, it is essential to do the translation of this data into clinical research and some of its potential and critical gaps are discussed in this review pointing to large-scale and long-term clinical trials that should include more patients and homogeneous samples.
publishDate 2022
dc.date.none.fl_str_mv 2022-03-29
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/103190
http://hdl.handle.net/10316/103190
https://doi.org/10.3390/biomedicines10040796
url http://hdl.handle.net/10316/103190
https://doi.org/10.3390/biomedicines10040796
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2227-9059
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134093779140608